US Rare Endocrinology & Tumors Medical Affairs Director

AstraZeneca; Boston (MA); On-site; USD 282,000 - 423,000; Full time

Job summary

AstraZeneca plc seeks an Executive Director, Head of US Rare Endocrinology and Rare Tumors to provide senior medical leadership and full US Medical Affairs strategic ownership for all in-country Medical Affairs activities.

This leader will define and implement the US strategy across marketed products, pipeline assets, and lifecycle initiatives, ensuring alignment with Global Medical Affairs and patient-centered objectives.

Qualifications

• Advanced scientific or clinical degree (MD, PharmD, PhD, or equivalent).
• 12+ years in biopharmaceutical industry with Medical Affairs leadership.
• 10+ years leading Medical Affairs teams.
• Rare disease experience strongly preferred.
• Ability to influence senior leaders and cross-functional partners.
• Proven use of digital, data, and AI-enabled capabilities.

Responsibilities

• Define and implement US Medical Affairs strategy across portfolio and lifecycle.
• Lead strategy and tactical plans for Rare Endocrinology and Rare Tumors in the US.
• Represent US Medical Affairs in leadership forums and cross-functional planning.
• Develop and grow a high-performing Medical Affairs team.
• Align portfolio priorities, budgets, and resource needs with patient impact.
• Collaborate with Commercial, HEOR, Regulatory, Clinical Development, and Global Medical Affairs.
• Lead launch readiness, lifecycle management, and evidence generation activities.
• Oversee publication planning and medical communications for global and US strategy.
• Drive external expert engagement, thought leader development, and scientific exchange.
• Translate insights into strategic actions to improve patient care.

Skills

Leadership

Strategy

Stakeholder mgmt

Digital AI

Communication

Education

Advanced clinical degree

Job description

AstraZeneca plc seeks an Executive Director, Head of US Rare Endocrinology and Rare Tumors to provide senior medical leadership and full US Medical Affairs strategic ownership for all in-country Medical Affairs activities.

This leader will define and implement the US strategy across marketed products, pipeline assets, and lifecycle initiatives, ensuring alignment with Global Medical Affairs and patient-centered objectives.